首页 | 本学科首页   官方微博 | 高级检索  
     


Evolving concepts in cancer therapy through targeting sphingolipid metabolism
Authors:Jean-Philip Truman,Mó  nica Garcí  a-Barros,Lina M. Obeid,Yusuf A. Hannun
Affiliation:1. Health Science Center, Stony Brook University, 100 Nicolls Road, T15, 023, 11794 Stony Brook, NY, USA;2. Northport Veterans Affairs Medical Center, Northport, NY 11768, USA;3. Health Science Center, Stony Brook University, 100 Nicolls Road, L4, 178, 11794 Stony Brook, NY, USA;4. Department of Medicine and the Stony Brook Cancer Center, Health Science Center, Stony Brook University, 100 Nicolls Road, L4, 178, 11794 Stony Brook, NY, USA
Abstract:Traditional methods of cancer treatment are limited in their efficacy due to both inherent and acquired factors. Many different studies have shown that the generation of ceramide in response to cytotoxic therapy is generally an important step leading to cell death. Cancer cells employ different methods to both limit ceramide generation and to remove ceramide in order to become resistant to treatment. Furthermore, sphingosine kinase activity, which phosphorylates sphingosine the product of ceramide hydrolysis, has been linked to multidrug resistance, and can act as a strong survival factor. This review will examine several of the most frequently used cancer therapies and their effect on both ceramide generation and the mechanisms employed to remove it. The development and use of inhibitors of sphingosine kinase will be focused upon as an example of how targeting sphingolipid metabolism may provide an effective means to improve treatment response rates and reduce associated treatment toxicity. This article is part of a Special Issue entitled Tools to study lipid functions.
Keywords:ACDase, acid ceramidase   ASMase, acid sphingomyelinase   C1P, ceramide1-phosphate   CAPP, ceramide activated protein phosphatase   CerS, ceramide synthase   CERT, ceramide transfer protein   DHS, L-threo-dihydrosphingosine   DMS, D-erythro-N,N-dimethylsphingosine   GCS, glucosyl ceramide synthase   KO, knockout   MDR, multi drug resistance   NADPH, nicotinamide adenine dinucleotide phosphate   nSMase, neutral sphingomyelinase   OE, N-oleoylethanolamine   PKC, protein kinase C   PPMP, DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol   RNAi, interfering RNA   S1P, sphingosine 1-phosphate   S1PR, sphingosine 1-phosphate receptor   siRNA, small interfering RNA   SMase, sphingomyelinase   SK1/2, sphingosine kinase 1/2   SKI-II, 2-(p-hydroxyanilino)-4-(p-chlorophenyl)-thiazole   TNFα, tumor necrosis factor α
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号